CN1268623C - 组合物和使该组合物稳定的方法 - Google Patents

组合物和使该组合物稳定的方法 Download PDF

Info

Publication number
CN1268623C
CN1268623C CNB008143137A CN00814313A CN1268623C CN 1268623 C CN1268623 C CN 1268623C CN B008143137 A CNB008143137 A CN B008143137A CN 00814313 A CN00814313 A CN 00814313A CN 1268623 C CN1268623 C CN 1268623C
Authority
CN
China
Prior art keywords
compound
glyceryl ester
composition
ester
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB008143137A
Other languages
English (en)
Chinese (zh)
Other versions
CN1379769A (zh
Inventor
上野隆司
波部豪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22573018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1268623(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CN1379769A publication Critical patent/CN1379769A/zh
Application granted granted Critical
Publication of CN1268623C publication Critical patent/CN1268623C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB008143137A 1999-10-15 2000-10-13 组合物和使该组合物稳定的方法 Ceased CN1268623C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15954999P 1999-10-15 1999-10-15
US60/159,549 1999-10-15

Publications (2)

Publication Number Publication Date
CN1379769A CN1379769A (zh) 2002-11-13
CN1268623C true CN1268623C (zh) 2006-08-09

Family

ID=22573018

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008143137A Ceased CN1268623C (zh) 1999-10-15 2000-10-13 组合物和使该组合物稳定的方法

Country Status (26)

Country Link
US (5) US6583174B1 (enExample)
EP (2) EP1220849B1 (enExample)
JP (2) JP4332316B2 (enExample)
KR (1) KR100830061B1 (enExample)
CN (1) CN1268623C (enExample)
AR (3) AR026046A1 (enExample)
AT (2) ATE267189T1 (enExample)
AU (2) AU780342B2 (enExample)
BR (1) BRPI0014869B8 (enExample)
CA (1) CA2385732C (enExample)
CZ (1) CZ303625B6 (enExample)
DE (2) DE60039727D1 (enExample)
DK (2) DK1426361T4 (enExample)
ES (2) ES2309410T5 (enExample)
HK (1) HK1045693B (enExample)
HU (2) HU230484B1 (enExample)
IL (2) IL148803A0 (enExample)
MX (1) MXPA02003756A (enExample)
NO (1) NO330258B1 (enExample)
NZ (1) NZ518020A (enExample)
PT (2) PT1220849E (enExample)
RU (1) RU2695274C3 (enExample)
TR (1) TR200201032T2 (enExample)
TW (1) TWI281918B (enExample)
WO (1) WO2001027099A2 (enExample)
ZA (1) ZA200202312B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1220849E (pt) * 1999-10-15 2004-10-29 Sucampo Ag Composicao de compostos biciclicos e metodo para a sua estabilizacao
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
US8114911B2 (en) * 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
ES2591252T3 (es) * 2002-12-27 2016-11-25 Sucampo Ag Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CN101198334B (zh) * 2005-04-12 2013-02-06 苏坎波公司 前列腺素化合物和质子泵抑制剂用于治疗肠胃病的联合应用
NZ570190A (en) 2006-01-24 2011-03-31 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
JP4783794B2 (ja) * 2006-01-24 2011-09-28 株式会社アールテック・ウエノ 軟ゼラチンカプセル製剤
EP2735566A1 (en) * 2006-02-07 2014-05-28 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
JP5390519B2 (ja) * 2007-07-19 2014-01-15 株式会社アールテック・ウエノ １１−デオキシ−プロスタグランジン化合物を含む医薬組成物およびその安定化方法
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
EP2653468B1 (en) 2009-07-28 2016-02-24 Ono Pharmaceutical Co., Ltd. Bicyclic Compound and Use Thereof for Medical Purposes
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
US8940790B2 (en) 2009-11-03 2015-01-27 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
US9029574B2 (en) 2011-01-27 2015-05-12 Ono Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
ES2581852T3 (es) 2011-01-27 2016-09-07 Ono Pharmaceutical Co., Ltd. Compuesto bicíclico y uso del mismo para fines médicos
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US10899729B2 (en) 2016-06-30 2021-01-26 Ono Pharmaceutical Co.. Ltd. Method for producing bicyclic compound
WO2018065826A1 (en) 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
CA3097927A1 (en) * 2018-05-01 2019-11-07 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
WO2019221215A1 (ja) * 2018-05-18 2019-11-21 ニプロ株式会社 ルビプロストン含有粒子状医薬組成物
JP7518661B2 (ja) * 2020-05-14 2024-07-18 沢井製薬株式会社 ルビプロストン含有整粒物、ルビプロストン含有錠剤およびそれらの製造方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18202A (en) * 1857-09-15 Improvement in feathering paddle-wheels
JPS5720305B2 (enExample) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
US3966962A (en) 1975-03-27 1976-06-29 The Upjohn Company Triacetin solutions of PGE-type compounds
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5919524B2 (ja) 1976-12-17 1984-05-07 中外製薬株式会社 安定な１α−ヒドロキシビタミンＤ類含有製剤
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
CA1184906A (en) * 1977-04-19 1985-04-02 Roy A. Johnson 9-deoxy-5,9-epoxy-prostaglandins
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
JPS5452717A (en) * 1977-09-29 1979-04-25 Chugai Pharmaceut Co Ltd Stable oily pharmaceuticals containing 1alpha-hydroxyvitamin d
US4130566A (en) 1977-10-27 1978-12-19 Sumitomo Chemical Company, Limited Process for producing 5-carboxy-2-acetylthiophene
AT358530B (de) 1978-04-25 1980-09-10 Plc Pharma Licences Stabilisierungsverfahren
JPS55136219A (en) 1979-04-11 1980-10-23 Sumitomo Chem Co Ltd Diazepam oily drug
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
JPS59137413A (ja) * 1983-01-25 1984-08-07 Teijin Ltd ７−チアプロスタグランジンｅ↓１類を含有する医薬品組成物
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
ATE109970T1 (de) 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
GB2210556B (en) 1987-10-02 1991-07-17 Ueno Seiyaku Oyo Kenkyujo Kk The use of 15-keto-16-halo-prostaglandins in cathartic compositions
JP2597649B2 (ja) † 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
KR0158870B1 (ko) * 1988-06-17 1998-12-01 마틴 에이. 로쓰블랫 폐순환 승압의 치료, 예방 또는 진단용 조성물
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
JPH0745504B2 (ja) * 1988-07-29 1995-05-17 株式会社上野製薬応用研究所 プロスタグランジン前駆体およびその製法
JP2794433B2 (ja) 1989-02-02 1998-09-03 丸善製薬株式会社 甘草疎水性フラボノイド製剤
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
US5256696A (en) 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030344C (en) † 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JPH0446122A (ja) 1990-06-13 1992-02-17 Nippon Iyakuhin Kogyo Kk 活性型ビタミンｄ↓３類含有製剤
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
JP2746800B2 (ja) * 1991-09-03 1998-05-06 株式会社アールテック・ウエノ プロスタグランジン中間体の製法
US5274130A (en) * 1991-09-03 1993-12-28 R-Tech Ueno Ltd. Process for production of prostaglandin intermediates
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
PT1220849E (pt) * 1999-10-15 2004-10-29 Sucampo Ag Composicao de compostos biciclicos e metodo para a sua estabilizacao
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4210631B2 (ja) 2004-06-24 2009-01-21 株式会社日立製作所 ブレーキ制御装置

Also Published As

Publication number Publication date
AU2004242503C1 (en) 2005-01-27
US20080255227A1 (en) 2008-10-16
MXPA02003756A (es) 2005-09-08
ZA200202312B (en) 2002-12-24
EP1426361B1 (en) 2008-07-30
DE60039727D1 (de) 2008-09-11
NZ518020A (en) 2004-02-27
JP2003511445A (ja) 2003-03-25
US20040235885A1 (en) 2004-11-25
NO20021736L (no) 2002-04-12
KR20020068521A (ko) 2002-08-27
ATE402925T2 (de) 2008-08-15
TR200201032T2 (tr) 2002-08-21
KR100830061B1 (ko) 2008-05-16
RU2695274C9 (ru) 2020-01-22
AU780342B2 (en) 2005-03-17
AU7685600A (en) 2001-04-23
AU2004242503B2 (en) 2007-06-21
CN1379769A (zh) 2002-11-13
EP1426361A1 (en) 2004-06-09
PT1220849E (pt) 2004-10-29
TWI281918B (en) 2007-06-01
US20120095090A1 (en) 2012-04-19
EP1220849B1 (en) 2004-05-19
US8088934B2 (en) 2012-01-03
HK1045693B (en) 2005-01-21
DE60010913D1 (de) 2004-06-24
IL148803A0 (en) 2002-09-12
CA2385732C (en) 2009-02-10
WO2001027099A2 (en) 2001-04-19
RU2695274C3 (ru) 2020-11-09
JP2009235079A (ja) 2009-10-15
BRPI0014869B8 (pt) 2021-05-25
US7417067B2 (en) 2008-08-26
RU2002112984A (ru) 2004-01-20
DK1220849T3 (da) 2004-09-27
HK1045693A1 (en) 2002-12-06
BR0014869A (pt) 2002-06-25
EP1426361B2 (en) 2015-02-25
US6583174B1 (en) 2003-06-24
PT1426361E (pt) 2008-10-08
HK1066792A1 (en) 2005-04-01
ATE267189T1 (de) 2004-06-15
DK1426361T3 (da) 2008-11-17
ES2309410T3 (es) 2008-12-16
HUP0203746A3 (en) 2005-02-28
HU229547B1 (en) 2014-01-28
WO2001027099A3 (en) 2001-10-25
HU230484B1 (hu) 2016-07-28
US8097649B1 (en) 2012-01-17
IL148803A (en) 2006-07-05
NO330258B1 (no) 2011-03-14
EP1220849A2 (en) 2002-07-10
ES2221859T3 (es) 2005-01-16
RU2695274C2 (ru) 2019-07-22
AR089848A2 (es) 2014-09-24
AR109354A2 (es) 2018-11-21
NO20021736D0 (no) 2002-04-12
HUP0203746A2 (hu) 2003-03-28
ES2309410T5 (es) 2015-03-17
JP4332316B2 (ja) 2009-09-16
DE60010913T2 (de) 2005-06-09
DK1426361T4 (en) 2015-03-16
AU2004242503A1 (en) 2005-01-27
CZ20021037A3 (cs) 2002-09-11
CA2385732A1 (en) 2001-04-19
AR026046A1 (es) 2002-12-26
CZ303625B6 (cs) 2013-01-16
HUP1300369A2 (enExample) 2003-03-28
BRPI0014869B1 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
CN1268623C (zh) 组合物和使该组合物稳定的方法
CN1146423C (zh) 前列腺素产品
CN100335049C (zh) 泻药组合物
CN1767856A (zh) 用作c型肝炎病毒蛋白酶抑制剂的药物组合物
CN1093901A (zh) 烟霉醇衍生物的稳定药物组合物
CN1026984C (zh) 偏端霉素衍生物的制备方法
CN1237106A (zh) 含有4,5－环氧吗啡喃衍生物的稳定的药物组合物
CN1330648A (zh) 作为jnk蛋白质激酶抑制剂的4－芳基羟吲哚
CN101076329A (zh) 纯化反－(－)－△9－四氢大麻酚和反－(+)－△9－四氢大麻酚的方法
CN1627959A (zh) 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
CN1095712A (zh) 四氢咔唑衍生物
CN1522147A (zh) 含有15-酮基-前列腺素类化合物的用于治疗药物诱导的便秘的组合物
CN101056633A (zh) 用于贫血治疗的PI3激酶γ抑制剂
CN1681783A (zh) 2,4－取代吲哚和它们作为5－ht6调节剂的用途
CN1047866A (zh) N-杂芳基-嘌呤-6-胺的制备方法及其药用
CN1214017C (zh) 四唑衍生物
CN1500085A (zh) 降低脂质的联苯基甲酰胺
CN1044705C (zh) (1-苯基-1-杂环基)烷烃衍生物、它们的制备方法及其用途
CN1489461A (zh) 甘油三酸酯降低剂组合物
CN1126545C (zh) 眼科用制剂
CN1960974A (zh) 烷基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途
CN1763027A (zh) 新抗坏血酸化合物，合成方法及其应用
CN1025032C (zh) 制备2-甲氧基甲基-青霉烯衍生物的方法
CN1240379C (zh) 过氧化脂质降低剂组合物
CN1126991A (zh) 新的(1-苯基-1-杂环基)甲醇和(1-苯基-1-杂环基)甲胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C35 Partial or whole invalidation of patent or utility model
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20141230

Decision number of declaring invalidation: 24743

Granted publication date: 20060809